Synthesis Capital
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Synthesis Capital.
Key people at Synthesis Capital.
Synthesis Capital refers to two distinct investment firms operating in different sectors and geographies:
1. Synthesis Capital (Medtech/Healthtech, Australia, founded 2023)
This Synthesis Capital is a venture capital firm based in Melbourne, Australia, focusing on early-stage investments in medtech, healthtech, and wellbeing sectors across the Asia-Pacific region. Its mission is to transform global healthcare by investing in deep technology startups from pre-seed to Series A+ stages. The firm uniquely blends financial investment with venture development services, leveraging an exclusive partnership with the MedTech Actuator to access a pipeline of high-growth startups. It targets financial returns exceeding 25% net of fees while optimizing health impact and systemic transformation in healthcare[1][2].
2. Synthesis Capital (Food Tech/Biotech, London, founded 2014)
This London-based Synthesis Capital invests in visionary founders transforming the food system through food technology and modern biotechnology. It supports startups pioneering sustainable, resilient food production and processing innovations, including alternative proteins and biotech solutions. The firm brings deep investment experience and technical expertise to guide startups in navigating the nascent food tech industry. It has a track record of backing category leaders and new entrants globally, aiming to redefine the future of food[3][5][6].
---
Medtech/Healthtech Synthesis Capital invests in early-stage ventures that develop technologies to enhance longevity, social care, human augmentation, and climate change adaptation in health systems. It serves startups and investors seeking both financial returns and positive health impact, addressing challenges like inclusive social support and preventive care[1][2].
Food Tech/Biotech Synthesis Capital backs companies creating innovative food technologies that solve problems related to sustainability, nutrition, and food system resilience. It serves founders developing plant-based, cultivated, recombinant, and single-cell food technologies, aiming to revolutionize how food is grown and consumed[3][5].
---
Medtech/Healthtech Synthesis Capital was founded in 2023 in Melbourne. It evolved from Australia's MedTech Actuator, a national medtech venture catalyst, now a leading Asia-Pacific healthtech commercialization initiative. The firm’s founding partners leveraged this ecosystem to create a venture capital model that combines investment with active risk management and milestone-based scaling[1][2].
Food Tech/Biotech Synthesis Capital was founded in 2014 in London by experienced investors including Managing Partner Costa Yiannoulis and Partner Rosie Wardle. The firm emerged from prior involvement with CPT Capital, a pioneer in alternative protein investments. This background shaped its focus on deep tech food innovations and a hands-on approach guiding startups from lab to market[3][6].
---
---
Medtech/Healthtech Synthesis Capital rides the trend of digital health, longevity, and climate-adaptive healthcare technologies, addressing urgent global health system challenges. Its timing is critical as health systems seek sustainable, tech-driven solutions post-pandemic, with growing investor interest in impact-driven health ventures[1][2].
Food Tech/Biotech Synthesis Capital capitalizes on the rising demand for sustainable food production amid climate change and population growth. It supports the shift from traditional agriculture to biotech-enabled food systems, influencing the global food ecosystem by accelerating innovation in alternative proteins and food sustainability[3][5].
---
Medtech/Healthtech Synthesis Capital is poised to expand its influence in the Asia-Pacific healthtech sector by scaling startups that deliver both strong financial returns and systemic health impact. Future trends like aging populations, climate resilience, and personalized health will shape its portfolio and investment strategy[1][2].
Food Tech/Biotech Synthesis Capital will likely deepen its role as a key investor in the evolving food tech landscape, supporting breakthroughs in cellular agriculture and sustainable food systems. Its influence may grow as global food security and environmental concerns drive demand for innovative food technologies[3][5].
Both firms exemplify a synthesis of financial rigor and sector-specific expertise, aiming to transform their respective industries through strategic early-stage investments.
Key people at Synthesis Capital.
